Northwire Canada EditionFriday, July 10, 2026
Sign inSubscribe
Northwire
⌕
ABX 51.81 −0.8% TTS 2.50 +0.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.82 +9.7% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.45 +0.3% SGZ 0.045 +0.0% S 0.160 +33.3% GRSL 0.315 −1.6% DEX 0.395 +2.6% WMS 0.040 +0.0% EMPR 0.830 +1.2% ABX 51.81 −0.8% TTS 2.50 +0.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.82 +9.7% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.45 +0.3% SGZ 0.045 +0.0% S 0.160 +33.3% GRSL 0.315 −1.6% DEX 0.395 +2.6% WMS 0.040 +0.0% EMPR 0.830 +1.2%
M&A / Property Neutral

Noveris Health Sciences Provides Corporate Update

Noveris Health Sciences Re-Engages R&D Partner on Psilocybin Pipeline Amid Stem Cell Pivot and Insider Sell-Off

By The Northwire Desk — AI Analysis Jun 05, 2026 · 16:20 NVRS · 2.86 Noveris Health Sciences Inc.
Executive Summary
  • Noveris Health Sciences re-engaged Applied Pharmaceutical Innovation (API) under a master services agreement effective May 27, 2026.
  • The company will pay a $20,000 retainer and allocate a minimum of $100,000 for R&D consultancy through the end of fiscal 2026, with no minimum or maximum spend requirements.
  • Management is evaluating transaction structures to acquire a 49% equity interest in Ell Stem Cells for $1 million USD, though no definitive agreement has been executed.
  • Immediate corporate priority remains advancing the existing psilocybin IP portfolio and renewed API collaboration over stem cell initiatives.
Material Impact
  • The $120,000 total commitment to API is immaterial relative to the $2.31 million raised in the March 2026 private placement.
  • This announcement is a direct follow-up to the April 20, 2026 clarification that R&D activities were paused due to funding constraints.
  • The market was already aware of the LIFE Offering proceeds and the strategic pivot toward stem cell distribution.
  • The news does not introduce new capital, regulatory milestones, or commercial partnerships. It is an incremental operational update that aligns with previous guidance.
  • Combined with the recent 99% reduction in former CEO Joshua Bartch's stake, the sentiment leans toward capital preservation rather than aggressive growth.
NVRS · Price
Company Overview
  • Noveris Health Sciences is a pre-revenue biotechnology company focused on developing novel psychedelic-inspired compounds for mental health treatment.
  • Flagship Project: A psilocybin-related intellectual property portfolio consisting of 3 issued patents and 13 pending patent applications focused on compounding, synthesizing, and therapeutic uses.
  • Secondary Initiative: Exploring regenerative medicine through a potential stake in ELL Stem Cells, a registered tissue bank and distributor of extracellular matrices and exosomes.
Read the original news release →

More from Noveris Health Sciences Inc.

May 21, 2026 · 14:12

Founder cashes out completely after boardroom shake‑up, casting a dark shadow over the sudden stem‑cell pivot.

Other Apr 29, 2026 · 12:05

Noveris Health Sciences Inc.

M&A / Property Apr 20, 2026 · 17:25

Noveris Health Sciences Inc.

Regulatory Mar 18, 2026 · 20:20

Noveris Announces Closing of Life Offering

Financings Mar 11, 2026 · 22:58

Noveris Announces Life Offering

Financings Mar 10, 2026 · 16:05

Noveris Announces Resignation Of CEO

Management